Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Stock Is Soaring Again Today

By Keith Speights – Sep 16, 2020 at 11:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors remain enthusiastic about comments made earlier this week by Inovio's CEO.

What happened

Shares of Inovio Pharmaceuticals (INO -5.47%) were soaring 14.6% as of 11:02 a.m. EDT after jumping as much as 19.5% earlier in the day. This marked the third consecutive day of big gains for Inovio. What's behind the impressive momentum? Investors remain excited about comments made by Inovio CEO J. Joseph Kim at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday.

So what

Kim made two statements at the Wainwright conference that fired up investors. First, he said that a paper with detailed results of the phase 1 study of coronavirus vaccine candidate INO-4800 is currently in peer review and should be published within the next several weeks. Second, Kim stated that Inovio expects to begin phase 2/3 testing for the investigational vaccine soon and is "very confident that we will be able to do this with external funding."

Yellow sticky note with a drawing of a coronavirus and a chalk drawing of a dollar sign underneath it

Image source: Getty Images.

Some industry observers were skeptical about Inovio's interim results for the early-stage study of INO-4800 announced on June 30. The biotech didn't provide all of the details about immune responses in participants that they were hoping to hear. The forthcoming peer-reviewed publication could put those concerns to rest.

But the news investors really liked was that Inovio expects to obtain external funding for its phase 2/3 testing of INO-4800. Some are no doubt speculating that Inovio could receive federal funding from Operation Warp Speed, the U.S. government program established to accelerate coronavirus vaccine development. 

Now what

Despite this week's huge gains, Inovio's shares are still around 50% below its peak set in late June. However, the biotech stock could have multiple catalysts on the way that could enable it to move a lot higher. Federal funding for INO-4800 would especially provide a huge boost for the stock and tremendous validation for Inovio's coronavirus program. For now, though, investors have to, in the words of CEO Joseph Kim, "stay tuned" for what happens next.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$1.90 (-5.47%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.